
    
      This is a phase 2, multicenter, randomized, double-blind placebo-controlled, parallel group
      study to determine the persistence of the effect of SNP on blood pressure and to assess the
      potential for rebound hypertension associated with prolonged infusion in pediatric subjects.

      The primary endpoint is the change in MAP during the Blinded Study Drug Administration Phase
      in the absence of other stimuli.
    
  